

In the Claims:

Please amend the claims as follows. Applicant has included herewith a complete claim set with insertions and deletions indicated by underlining and strikethrough (or double bracketing), respectively.

1. (Currently amended) An isolated polypeptide comprising an unbroken sequence of amino acids from SEQ ID. NO. 1, ~~or 2, characterised by an ability to complex~~ that complexes with a major histocompatibility complex molecule type HLA-A2, preferably HLA-A2.1.
2. (Currently amended) An isolated polypeptide comprising an unbroken sequence of amino acids from SEQ. ID. NO. 1, ~~or 2, characterised by an ability to elicit~~ that elicits an immune response from human lymphocytes.
3. (Canceled)
4. (Currently amended) A nonapeptide comprising an unbroken sequence of amino acids from SEQ. ID. NO. 1, ~~or 2,~~ wherein the amino acid adjacent to the N-terminal amino acid is L or M, ~~preferably L,~~ and the C-terminal amino acid is L, V, or I, ~~preferably L,~~ other than a nonapeptide having the sequence CLGLSYDGL (SEQ ID NO:57).
5. (Previously presented) A nonapeptide as claimed in claim 4, wherein the amino acid in position 3 is Y and/or the amino acid in position 4 is D and/or the amino acid in position 5 is G and/or the amino acid in position 7 is E and/or the amino acid in position 8 is H.
- 6.-8. (Canceled)
9. (Currently amended) A nonapeptide having the amino acid sequence GLYDGMEHL (SEQ ID NO:42) or GLYDGREHS (SEQ ID NO:43), ~~preferably GLYDGMEHL (SEQ ID NO:42).~~

10. (Currently amended) A decapeptide having the amino acid sequence GLYDGMEHLI (SEQ ID NO:44) or GLYDGREHSV (SEQ ID NO:45), preferably GLYDGMEHLI (SEQ ID NO:44).

11. (Previously presented) An isolated polypeptide of up to about 93 amino acids in length, characterised by comprising a nonapeptide as claimed in claim 4.

12. (Currently amended) An isolated [[A]] polypeptide as claimed in claim 11 comprising an unbroken sequence of amino acids from SEQ. ID. NO. 1, ~~or~~ 2.

13-16. (Canceled)

17. (Previously presented) An isolated polypeptide or protein comprising a polypeptide as claimed in claim 1, wherein the amino acid sequence of said isolated polypeptide or protein is not that set out in either of SEQ. ID. NOs. 1 and 2 or that coded for by nucleotides 334-918 of SEQ. ID. NO. 7.

18.-41. (Canceled)

42. (New) The nonapeptide of claim 4, wherein the amino acid adjacent to the N-terminal amino acid is L.

43. (New) The nonapeptide of claim 4, wherein the C-terminal amino acid is L.

44. (New) The isolated polypeptide of claim 1, the polypeptide being a nonapeptide wherein the amino acid adjacent to the N-terminal amino acid is L or M, and the C-terminal amino acid is L, V, or I.

45. (New) The isolated polypeptide of claim 44, wherein the amino acid adjacent to the N-terminal amino acid is L.

46. (New) The isolated polypeptide of claim 44, wherein the C-terminal amino acid is L.
47. (New) The isolated polypeptide of claim 2, the polypeptide being a nonapeptide wherein the amino acid adjacent to the N-terminal amino acid is L or M, and the C-terminal amino acid is L, V, or I.
48. (New) The isolated polypeptide of claim 47, wherein the amino acid adjacent to the N-terminal amino acid is L.
49. (New) The isolated polypeptide of claim 47, wherein the C-terminal amino acid is L.
50. (New) A polypeptide as claimed in claim 1, other than a nonapeptide having any one of amino acid sequences:
- (a) FLLFKYQMK (SEQ ID NO:48);
  - (b) FIEGYCTPE (SEQ ID NO:49); or
  - (c) GLEGAQAPL (SEQ ID NO:50).
51. (New) A decapeptide comprising the nonapeptide of claim 44.
52. (New) The isolated polypeptide of claim 1, wherein the polypeptide elicits an immune response from human lymphocytes.
53. (New) The isolated polypeptide of claim 52, wherein the polypeptide elicits an immune response from human lymphocytes when complexed with a major histocompatibility complex molecule type HLA-A2.
54. (New) The isolated polypeptide of claim 52, wherein the immune response is a cytolytic response from human T-lymphocytes.